Autoantibodies against DNA repair proteins may drive pediatric cancers
Researchers in Norway analyzed tumor and blood samples and found that many children with cancer produce autoantibodies against their own DNA repair proteins. These antibodies can enter living cells and appear to inhibit the proteins that normally fix genomic damage. The finding points to a possible new mechanism for pediatric cancer and a potential route to early screening.
Norwegian researchers examined proteins in tumor and blood specimens from 175 children and adults with sarcoma or acute lymphoblastic leukemia, plus healthy controls. Children aged 2–19 with cancer carried notably more IgG autoantibodies aimed at DNA-repair molecules, including RAD52, NUMA1, ALKBH7, APBB1, UNG, and MGMT.
In a separate British cohort of 59 school-age children, those who later developed cancer—on average six years after sampling—were roughly eight times more likely to have antibodies against at least one core DNA-repair antigen. The work appears in Frontiers in Immunology.
If confirmed, this mechanism could affect pediatric cancer screening and risk monitoring, especially for young children. Families might face earlier blood tests or surveillance, with potential benefits from earlier detection but also possible anxiety or overdiagnosis. Researchers and clinicians may gain a new biological target for studying prevention and treatment. These possibilities remain speculative until larger studies validate the findings.